Welcome to our dedicated page for Kura Oncology news (Ticker: KURA), a resource for investors and traders seeking the latest updates and insights on Kura Oncology stock.
Kura Oncology, Inc. reports news on its precision oncology business, including commercialization of KOMZIFTI™ (ziftomenib), an FDA-approved once-daily oral menin inhibitor for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. Company updates also cover small-molecule drug candidates designed to target cancer signaling pathways across hematologic malignancies and solid tumors.
Recurring KURA developments include financial results, corporate updates, clinical data presentations, collaboration-related milestones, healthcare conference participation and Nasdaq inducement grants. News on darlifarnib (KO-2806) follows the company’s farnesyl transferase inhibitor program, including studies in combination with cabozantinib for clear cell renal cell carcinoma.
Kura Oncology, a clinical-stage biopharmaceutical company focused on precision cancer medicine, will participate in the JMP Securities Hematology Summit on December 15, 2020. CEO Troy Wilson will take part in a fireside chat at 11:00 a.m. ET. The summit is hosted virtually from December 15-16, 2020. A live audio webcast of the discussion will be available on Kura's website, with a replay accessible for 30 days. Kura's leading drug candidate is tipifarnib, aimed at treating HRAS mutant head and neck squamous cell carcinoma, alongside KO-539 for acute myeloid leukemia.
Kura Oncology (Nasdaq: KURA) has announced the pricing of an underwritten public offering of 8,110,000 shares of its common stock at $37.00 per share, aiming for gross proceeds of approximately $300 million. The offering includes a 30-day option for underwriters to purchase an additional 1,216,500 shares. The expected closing date is December 11, 2020, pending customary conditions. The securities are offered under a previously filed shelf registration statement.
Kura Oncology, Inc. (Nasdaq: KURA) has initiated an underwritten public offering to sell $200 million in common stock, with an option for underwriters to purchase an additional $30 million. The offering is subject to market conditions, and no assurance is given regarding its completion. The shares will be offered under a shelf registration statement filed with the SEC. The transaction will be managed by SVB Leerink, Credit Suisse, Barclays, and Stifel.
Kura Oncology announced preliminary data from its Phase 1/2A clinical trial of KO-539, an oral menin inhibitor, for treating relapsed/refractory acute myeloid leukemia (AML). Encouraging results showed evidence of biologic activity in all dose-escalation cohorts, with two complete remissions (CR) in patients with specific genetic mutations. The continuous dosing of KO-539 was well tolerated with manageable safety, and Kura plans to recommend a Phase 2 dose and advance to expansion cohorts in early 2021.
Kura Oncology will host a virtual investor event on December 5, 2020, at 2:00 p.m. ET to discuss preliminary clinical data regarding its menin inhibitor, KO-539, following its presentation at the 62nd American Society of Hematology (ASH) Annual Meeting. The event will feature Kura's management team and investigators from the ongoing KOMET-001 trial. A live video webcast will be available on Kura's website, with an archived replay accessible after the event.
Kura Oncology reported third quarter 2020 results, highlighting significant developments in its clinical pipeline and financial standing. Preliminary data from the KOMET-001 trial of KO-539, a menin inhibitor, showed promising safety and anti-leukemic activity. The drug is nearing a recommended Phase 2 dose with expansion cohorts planned for specific AML populations. Additionally, preclinical data supports the combination of tipifarnib with a PI3Kα inhibitor for treating HRAS-dependent HNSCC. Kura ended Q3 2020 with $325.4 million in cash, ensuring operational support into 2023.
Kura Oncology, Inc. (Nasdaq: KURA) announced participation in three upcoming virtual investor conferences. CEO Troy Wilson will present at the Credit Suisse 29th Annual Healthcare Conference on November 11, 2020, at 10:15 a.m. ET. CFO Marc Grasso will speak at the Stifel Virtual Healthcare Conference on November 16, 2020, at 1:20 p.m. ET. Additionally, a pre-recorded fireside chat with Dr. Wilson will be available on Kura's website during the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. Live audio webcasts will also be accessible on Kura's IR website.
Kura Oncology (KURA) will release its third quarter 2020 financial results on November 5, 2020, before U.S. markets open. A conference call and webcast will follow at 8 a.m. ET to discuss the results and provide a corporate update. The company focuses on developing precision cancer treatments, with its lead candidate, tipifarnib, in a registration-directed trial for HRAS mutant head and neck cancer. Kura also has KO-539, a menin inhibitor in Phase 1/2A trials for acute myeloid leukemia.
Kura Oncology has unveiled new preclinical data supporting the use of tipifarnib in treating HRAS/PI3K-dependent tumors, which account for up to 50% of head and neck squamous cell carcinoma (HNSCC) cases. The company plans to initiate a Phase 1/2 proof-of-concept study combining tipifarnib with a PI3Kα inhibitor in relapsed/refractory HNSCC. Current estimates suggest that 20% of HNSCC patients overexpress HRAS while 35% have PIK3CA mutations. Kura's ongoing AIM-HN trial focuses on HRAS mutant HNSCC, which affects 4-8% of patients.
Kura Oncology, a clinical-stage biopharmaceutical company, announced that preliminary data from its KOMET-001 study will be presented at the 62nd ASH Annual Meeting on December 5, 2020. This ongoing trial evaluates the safety and efficacy of KO-539, an oral menin inhibitor for patients with relapsed/refractory acute myeloid leukemia (AML). Data will be available on the ASH website on November 5, 2020. The presentation aims to assess anti-leukemic activity in specific genetic subgroups, highlighting the potential of KO-539 in addressing high unmet medical needs.